Total Live Articles: 503

Acute Heart Failure

NICE guidelines [CG187] Acute heart failure: diagnosis and management. Last updated: Nov 2021.

Separate section on acute cardiogenic shock has been added.

Date: 25/02/26

Acute Heart Failure

Acute heart failure is a rapid onset or worsening of heart failure symptoms caused by the heart’s inability to pump blood effectively, often leading to pulmonary oedema, fluid overload, or cardiogenic shock.

This article covers the causes, signs/symptoms, diagnosis, investigations, and emergency management of acute heart failure in clinical practice.

Diagnosis and management is based on available NICE guidelines [CG187] Acute heart failure: diagnosis and management.

Background Information

Definition

There are 2 main types of acute heart failure:

  • De novo acute heart failure: sudden onset of heart failure in someone with no history or diagnosis of heart failure
  • Acute decompensated chronic heart failure: acute worsening of symptoms in someone with established chronic heart failure

Causes

De Novo Acute Heart Failure

  • Acute coronary syndrome (esp. myocardial infarction) – most common and important
  • Acute valvular disease
  • Acute myocarditis
  • Arrhythmias

Acute Decompensated Chronic Heart Failure

  • Acute infections (e.g. respiratory tract infection, UTI)
  • Non-adherence to medication / dietary restrictions
  • Atrial fibrillation and other arrhythmias
  • Acute coronary syndrome
  • Uncontrolled hypertension
  • Anaemia

Complications

Main complications are:

  • Haemodynamic instability (can cause cardiogenic shock)
  • Pulmonary congestion
  • End-organ hypoperfusion

Diagnosis

Clinical Features

Symptoms

Pulmonary and systemic congestion are the main presenting features:

  • Pulmonary congestion (from left ventricular failure)
    • Sudden onset dyspnoea and orthopnoea
    • Cough +/- pink frothy sputum
  • Systemic congestion (from right ventricular failure)
    • Peripheral oedema
    • Weight gain

Examination Findings

Pulmonary and systemic congestion are the main presenting features:

  • Pulmonary congestion (from left ventricular failure)
    • Bi-basal crackles
    • Cardiac wheeze
    • S3 gallop rhythm
  • Systemic congestion (from right ventricular failure)
    • Raised JVP
    • Peripheral oedema
    • Ascites
    • Congestive hepatopathy

Investigation and Diagnosis

Initial test: chest X-ray

  • Chest X-ray can be used to support the diagnosis of heart failure and exclude alternative diagnoses
  • A combination of typical clinical features and chest X-ray findings is usually sufficient to diagnose acute heart failure and initiate treatment
  • Typical chest X-ray findings in heart failure are (ABCDE):
    • A: Alveolar oedema (perihilar bat wing opacities – from fluid accumulation in alveolar spaces)
    • B: Kerley B lines (short horizontal lines at peripheral lung margins – from interstitial oedema)
    • C: Cardiomegaly (>50% of thoracic width) (NB heart size can ONLY be assessed in a PA chest X-ray)
    • D: Dilated upper lobe vessels (↑ left atrial pressure → redistribution of blood to upper lobes)
    • E: Pleural effusion (typically bilateral transudative effusion)

Confirmatory test: transthoracic echocardiogram [NICE CG187]

  • In cases of de novo acute heart failure → consider performing  within 48 hours of admission to guide early specialist management

Role of serum BNP or NT-proBNP [NICE CG187]

  • It is recommended to help exclude heart failure
  • Heart failure would increase the levels of BNP and NT-proBNP, therefore heart failure is unlikely if the levels are NOT elevated (BNP < 100 ng/L or NT-proBNP < 300 ng/L)

Since many other conditions may raise BNP and NT-proBNP levels (e.g. CKD, COPD, pulmonary embolism); role of serum BNP or NT-proBNP is limited to excluding heart failure (i.e. an elevated serum BNP or NT-proBNP level is NOT diagnostic of heart failure alone)

Do NOT routinely offer pulmonary artery catheterisation to patients with acute heart failure [NICE CG187]

Other tests: [NICE CG187]

  • Blood tests
    • FBC (anaemia can cause / worsen dyspnoea and exacerbate heart failure; ↑ WCC may suggest an underlying infection)
    • U&Es (detect renal impairment, which may cause / worsen fluid overload)
    • LFTs (heart failure may cause congestive hepatopathy)
    • TFT (thyroid dysfunction can affect cardiac function; hyperthyroidism can also precipitate AF)
    • Lipid profile (to identify dyslipidaemia as coroanry artery disease is an important cause of heart failure)
    • HbA1c (to identify diabetes, which is an important cardiovascular risk factor and influences heart failure management)
  • ECG (to assess for underlying / precipitating cardiac causes)
  • Urinalysis (to assess for renal disease)
  • PEF or spirometry (to assess for obstructive lung diseases as alternative or co-existing cause of dyspnoea)

Management

Acute Heart Failure

1st line: IV loop diuretic (furosemide 40-120 mg / bumetanide 1-3 mg) – to relieve congestive symptoms

 

Add-on therapy:

  • IV nitrates if there is:
    • Concomitant myocardial ischaemia, or
    • Severe hypertension, or
    • Aortic or mitral regurgitation
  • Ventilatory support
    • CPAP can be used in severe cardiogenic pulmonary oedema
    • Endotracheal intubation and mechanical ventilation – last resort

Do not routinely discontinue long-term heart failure medications, unless there are clear contraindications:

  • Beta blocker should be stopped if HR <50 bpm / shock / 2nd or 3rd degree heart block
  • ACE inhibitors should only be stopped if there is AKI / shock

Acute Cardiogenic Shock

1st line management: IV vasopressors (e.g. noradrenaline, adrenaline) or inotropes (e.g. dobutamine)

  • US guidelines recommend noradrenaline as 1st line, and only to add inotropes if ineffective [Ref]
  • Inotropes and vasopressors should be titrated to lowest effective dose (e.g. to maintain mean arterial pressure >65 mmHg)

Management beyond inotropes and vasopressors is complicated and individualised in intensive care setting, key principles are:

  • Treating underlying cause (e.g. revascularisation for myocardial infarction)
  • Early invasive hemodynamic assessment (e.g. pulmonary artery catheterisation) to guide management
  • Consideration for temporary mechanical circulatory support

Diuretics (e.g. furosemide) and vasodilators (e.g. nitrates) should generally be avoided in the initial management of cardiogenic shock with hypotension, as they may worsen perfusion and precipitate further hemodynamic compromise. [Ref]

References

Related Articles

Chronic Heart Failure

Shock

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

This is a staging environment

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.